According to The Antibody Society, 224 therapeutic antibodies have been approved or are under review in the United States or European Union, with more than half targeting membrane proteins.1,2
Membrane proteins play a critical role in essential cellular processes; representing approximately 23% of the human proteome, they are the focus of more than 60% of drugs on the market.3,4
Among these are transmembrane (TMEM) proteins, classified as integral proteins, which are permanently embedded within a lipid bilayer.
Acting as cell gateways, TMEM proteins facilitate the transport of molecules across the membrane and cell-to-cell communication via signal transduction and can influence drug delivery and absorption — an important consideration during drug development.5
Owing to their physiological significance, TMEM protein-targeting antibodies are being developed for a range of therapeutic indications, including cancers, cardiovascular diseases and neurological disorders.
Not yet a Subscriber?
This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.
Subscribe now Already a subscriber? Sign in here.